14 hours agoBusiness
33LENS
6 SourcesMumbai, India
thebalanced.newsMankind Pharma Q4 Profit Rises Over 30% on Chronic Therapy Demand; Nephrocare Reports 75% FY26 Profit Growth
Mankind Pharma reported a 30-32% year-on-year rise in consolidated net profit for Q4 FY26, driven by strong domestic demand for chronic therapies like cardiac and anti-diabetes drugs, and growth in consumer healthcare. Revenue increased around 12% to Rs 3,443 crore. The company’s acquisition of Bharat Serums and Vaccines contributed to performance. For FY26, Mankind’s net profit declined slightly despite a 17% revenue rise. Separately, Nephrocare Health Services posted a 75% profit increase in FY26, supported by higher dialysis volumes and international expansion amid rising chronic kidney disease cases.
Political Bias
0%100%0%
Sentiment
72%
AI Analysis
Political bias across 6 sources
● Left 0%● Center 100%● Right 0%
The articles primarily present corporate financial results with a focus on business performance and market factors, reflecting a neutral economic perspective. They include company statements and analyst commentary without political framing. The coverage emphasizes growth drivers and market conditions, representing corporate and investor viewpoints without partisan bias.
Sentiment — Positive (72/100)
The overall tone is positive, highlighting significant profit and revenue growth for both Mankind Pharma and Nephrocare Health Services. While Mankind’s full-year net profit showed a slight decline, the narrative centers on strong quarterly performance and market expansion. The sentiment is optimistic about chronic therapy demand and international growth, with no negative or critical language dominating the coverage.
How 4 sources covered this story
Each source's own headline, political lean, and sentiment — so you can see framing differences at a glance.
| Source | Their headline | Bias | Sentiment |
|---|---|---|---|
| economictimes | Mankind Pharma profit jumps 30 on chronic therapy demand in Q4 | Center | Positive |
| businessstandard | Mankind Pharma Q4 PAT rises 30 on strong domestic biz, chronic push | Center | Positive |
| businessstandard | Nephrocare Health Services profit up 75 in FY26 on strong dialysis demand | Center | Positive |
| freepressjournal | Mankind Pharma Reports 22 Revenue Growth, Net Profit Up 203 In Q4 FY26 | Center | Positive |
Coverage timeline
freepressjournal broke this story on 19 May, 02:07 pm. Other outlets followed.
- 1freepressjournal19 May, 02:07 pmMankind Pharma Reports 22 Revenue Growth, Net Profit Up 203 In Q4 FY26
- 2businessstandard19 May, 03:42 pmNephrocare Health Services profit up 75 in FY26 on strong dialysis demand
- 3businessstandard19 May, 06:56 pmMankind Pharma Q4 PAT rises 30 on strong domestic biz, chronic push
- 4economictimes19 May, 08:21 pmMankind Pharma profit jumps 30 on chronic therapy demand in Q4
Lens Score breakdown
33/100
Public interest0/100
Coverage gap90%
Well-covered story — coverage matches public importance.
Who's involved
Institutions and figures named across source coverage.
Corporate
CEO Sheetal AroraExecutive Chairman Ramesh JunejaBoard of DirectorsBharat Serums and VaccinesMankind Pharma LimitedNephrocare Health ServicesMankind PharmaNephroPlus
Story context
- Category
- Business
- Location
- Mumbai, India
- Sources analysed
- 6
- Last analysed
- 20 May 2026
- Key entities
- Mankind PharmaCroreIndian rupeeNet incomeChief executive officerVaccineIndiaZydus LifesciencesKidney dialysisKarnataka BankBharat PetroleumWestern Asia
Related Coverage
Select a news story to see related coverage from other media outlets.